Can I read Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice on EtoBox?

Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice by Patrick Davey; Mike G. Kirby is a Medicine article available to read on EtoBox.

What is Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice about?

## Abstract ## Purpose Androgen deprivation therapy (ADT) is the mainstay for the management of metastatic prostate cancer. Available pharmaceutical ADTs include gonadotropin-releasing hormone (GnRH) agonists and antagonists. Here, real-world data are presented from the UK general practitioner Optimum Patient Care Research Database. The study investigated the hypothesis that GnRH antagonists have lower cardiac event rates than GnRH agonists. ## Methods The incidence of cardiac events following initiation of GnRH antagonist or agonist therapy was investigated in a population-based cohort study conducted in UK primary care between 2010 and 2017. ## Results Analysis of real-world data from the UK primary care setting showed that relative risk of experiencing cardiac events was significantly lower with degarelix, a GnRH antagonist, compared with GnRH agonists (risk ratio: 0.39 [95% confidence interval 0.191, 0.799]; p = 0.01). Patients that received degarelix as first-line treatment switched treatment more frequently (33.7%), often to a GnRH agonist, than those who initiated treatment with a GnRH agonist (6.7–18.6%). ## Conclusion Screening for known or underlying vascular disease and

Who reads Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice?

Author

Patrick Davey; Mike G. Kirby

Publisher

Springer Science and Business Media LLC

Published

2020

Language

EN

Field

Medicine (Health Sciences)